Citations

Clear

941 citation(s) found for "Tan, B".

Associations of HER2-specific immunity with survival during treatment with trastuzumab and chemotherapy in breast cancer.
Knutson, Keith L. , Clynes, Raphael , Yeramian, Patrick, Kemp, Kathleen P., Shreeder, Barath , Tenner, Kathleen , Erskine, Courtney L. , Norton, Nadine , Northfelt, Donald W. , Tan, Winston , Pegram, Mark D. , Calfa, Carmen , Perez, Edith A. , Knutson, Keith L. , Ballman, Karla V. , Mittendorf, EA , Norton, Nadine

Mayo Clinic

Journal of Clinical Oncology | March 7, 2019 | Volume: 33 | Issue: 15_suppl | Pages: 587-587

10.1200/jco.2015.33.15_suppl.587 Get It

Plasma cell-free DNA-based prognosis in metastatic hormone sensitive prostate cancer.
Yadav, Siddhartha , Tan, Winston , Wang, Amy , Montesinos, Carlos, Wong, Calvin, Jia, Shidong , Yu, Jianjun , Yadav, Siddhartha , Kohli, Manish , Riaz, Irbaz Bin , Zheng, Tiantian , Du, Peter Pan

Mayo Clinic

Journal of Clinical Oncology | March 7, 2019 | Volume: 37 | Issue: 7_suppl | Pages: 242-242

10.1200/jco.2019.37.7_suppl.242 Get It

242 Background: We evaluated plasma cell free based genomic aberrations for prognosticating survival of newly diagnosed metastatic hormone sensitive prostate cancer (mHSPC) patients (pts). Methods: Plasma was collected from mHSPC pts enrolled between 2009-2014. Platelet poor plasma (PPP) fractions were processed uniformly and cell free DNA (cfDNA) extracted using Qiagen kits. Pts were followed after initiating hormonal therapy until death. Next Gen Sequencing (NGS) of cfDNA was performed using Illumina HiSeq X for a preselected panel of 128 genes (PredicineDDR-77 cancer driver genes; 29 genes in BRCA-FA homologous recombination deficiency (HRD) pathway; 22 DNA damage repair pathway genes). Statistical analyses of plasma genome based aberrations with overall survival (OS) were performed in R 3.5.1. Cox proportional-hazard models were used for survival analysis. Results: An average of 2.5 ml PPP from 99 pts yielded a median of 10.5 ng (range: 2.8-702) cfDNA per sample. 15/99 pt samples with a yield < 5 ng were excluded from sequencing; 9/99 samples failed NGS. Median follow-up time was 80.2 months (mths) (Range: 74.7, 87]); median OS was 69.1 mths (range: 54,NR). 29 pts with full NGS data had high volume metastatic disease. cfDNA yield correlated with metastatic volume (P = 0.01). Univariate analysis revealed both variables prognostic for OS (Metastatic volume: log-rank P=0.01, HR=2.1, 95% CI: 1.1-3.8; cfDNA yield: P =0.04, HR = 1.3, 95% CI: 1.03-1.7). Multivariate regression showed prognostic value of cfDNA yield remained independent of metastatic volume (P = 0.03, HR = 1.34, 95% CI: 1.02-1.76). 54/67 samples with NGS data had at least one mutation/copy number variation detected. Top mutated genes included TP53 (N=18), ATM (N=9), CHEK2 (N=7), FANCM (N=6), RB1 (N=6), BRCA2 (N=5), PIK3CA (N=4) and 37/67 pts harbored 1≥ variant in HDR pathways. These pts had a shorter survival (median: 58.6 mths) (P=0.04, HR= 2.28, 95% CI: 1.01-5.18) and pts with ATM mutations did significantly worse (median survival: 47.4 mths) (HR=4.03, P=0.0005, 95% CI: 1.73-9.37). Conclusions: Plasma cfDNA yield is prognostic for survival in newly diagnosed mHSPC state and presence of HRD pathway genomic aberrations in plasma cfDNA are associated with poor survival.
Quality of life analysis of NCCTG N0877 (Alliance): Phase II trial of either dasatinib or placebo combined with standard chemoradiotherapy for newly diagnosed glioblastoma multiforme (GBM).
Qin, Rui , Tan, Angelina D., Sloan, Jeff A. , Lesser, Glenn J. , Anderson, S. Keith , Johnson, Derek R. , Laack, Nadia N.

Mayo Clinic

Journal of Clinical Oncology | March 7, 2019 | Volume: 33 | Issue: 15_suppl | Pages: e17715-e17715

10.1200/jco.2015.33.15_suppl.e17715 Get It

Use of Eculizumab for Active Antibody-mediated Rejection That Occurs Early Post–kidney Transplantation: A Consecutive Series of 15 Cases
Tan, Ek Khoon , Bentall, Andrew , Dean, Patrick G. , Shaheen, Mohammed F. , Stegall, Mark D. , Stegall, Mark D , Bentall, Andrew , Schinstock, Carrie A.

Mayo Clinic

Transplantation | February 28, 2019 | Volume: 103 | Issue: 11 | Pages: 2397-2404

10.1097/tp.0000000000002639 | PMID 30801549 Get It

Background. Active antibody-mediated rejection (AMR) that occurs during the amnestic response within the first month posttransplant is a rare but devastating cause of early allograft loss after kidney transplant. Prior reports of eculizumab treatment for AMR have been in heterogeneous patient groups needing salvage therapy or presenting at varied time points. We investigated the role of eculizumab as primary therapy for active AMR early posttransplant. Methods. We performed a retrospective observational study of a consecutive cohort of solitary kidney transplant recipients who were transplanted between January 1, 2014, and January 31, 2018, and had AMR within the first 30 days posttransplant and treated with eculizumab ± plasmapheresis. Results. Fifteen patients had early active AMR at a median (interquartile range [IQR]) of 10 (7–11) days posttransplant and were treated with eculizumab ± plasmapheresis. Thirteen cases were biopsy proven, and 2 cases were presumed on the basis of donor-specific antibody trends and allograft function. Within 1 week of treatment, the median estimated glomerular filtration rate increased from 21 to 34 mL/min (P = 0.001); and persistent active AMR was only found in 16.7% (2/12) of biopsied patients within 4–6 months. No graft losses occurred, and at last follow-up (median [IQR] of 13 [12–19] mo), the median IQR estimated glomerular filtration rate increased to 52 (46–60) mL/min. Conclusions. Prompt eculizumab treatment as primary therapy is safe and effective for early active AMR after kidney transplant or abrupt increases in donor-specific antibodies when biopsy cannot be performed for diagnosis confirmation.
Percutaneous Pedicle Screw Fixation Alone Versus Debridement and Fusion Surgery for the Treatment of Early Spinal Tuberculosis: A Retrospective Cohort Study
Guo, Song , Zhu, Kai , Zhang, Shuya , Yang, Mingjie , Yan, Meijun , Li, Xinhua , Pan, Jie , Li, Lijun , Wang, Zhigang , Tan, Jun , Ma, Bin

Mayo Clinic

Medical Science Monitor | February 27, 2019 | Volume: 25 | Issue: No issue available | Pages: 1549-1557

10.12659/msm.912538 | PMID 30811378 Get It

Phase II Trial of Eribulin in Patients With Metastatic Hormone Refractory Prostate Cancer
Stein, Mark N. , Chen, Yu‐Hui , Hudes, Gary R., Lerma, Pauline Marie O., Tan, Winston , Dalune, Robert, Rowland, Kendrith M. , Kuzel, Timothy M. , DiPaola, Robert S. , Tan, Winston W., Carducci, Michael A.

Mayo Clinic

American Journal of Clinical Oncology | February 21, 2019 | Volume: 42 | Issue: 4 | Pages: 375-381

10.1097/coc.0000000000000526 | PMID 30789412 Get It

Background: Eribulin mesylate, a synthetic analog of halichondrin B, is a novel tubulin-binding agent that inhibits cancer cell proliferation at low-nanomolar levels. Methods: In a multicenter ECOG trial, patients with progressive metastatic CRPC, ECOG 0-2 were treated with eribulin 1.4 mg/m2 as an IV bolus over 5 minutes on days 1 and 8 of a 21-day cycle. This noncomparative study stratified points to either a chemonaive (CN), prior-taxane (Tax) only, or 2 prior cytotoxic (TCx) chemotherapy arm. The trial was powered to detect a 50% PSA reduction using Consensus Criteria in at least 40% versus 20% (90% power, one-sided α=0.10) for the CN stratum and 25% versus. 10% (power 87%, one-sided α=0.10) for the Tax and TCx strata. Results: In total, 119 pts received treatment of which 116 were eligible for the primary response determination in this study. Median age 70 years (range, 45 to 88); median number of treatment cycles 4 (range, 1 to 20+); ECOG 0-1 90%. Confirmed PSA response rates (50% decline from baseline) were 29% (90% [18.2%, 41.2%]; P=0.20), 10% (90% [5.2%, 27.1%]; P=1.00), and 4% ([0.2%, 18.3%]; P=0.59) in the chemonaive stratum, the prior-taxane stratum, and the 2-prior-chemotherapy stratum, respectively. Median progression-free survival was 3.5 months (95% CI, 2.0, 5.9), 2.3 months (95% CI, 2.0, 2.9) and 3.7 months (95% CI, 2.1, 4.2) for the chemonaive stratum, the prior-taxane stratum and the 2-prior-chemotherapy stratum, respectively. Nonhematological toxicities of any grade (mainly grade 1 and 2) were fatigue (74%), neuropathy (40%), alopecia (39%), nausea (35%), and anorexia (34%). Common hematological toxicities were decreased leukocytes (75%), decreased neutrophils (72%), and decreased hemoglobin (66%). The most common grade ≥ 3 toxicities were decreased neutrophils (55%), decreased leukocytes (42%), sensory neuropathy (13%), and fatigue (11%). Overall, there was a 4% rate of febrile neutropenia. Conclusions: In summary, per the prespecified study endpoints, eribulin did not have adequate activity in chemotherapy naïve or chemotherapy pretreated patients with metastatic CRPC to support further study in this setting.
Comprehensive Genetic Characterization of Human Thyroid Cancer Cell Lines: A Validated Panel for Preclinical Studies
Landa, Iñigo , Korch, Christopher , Smallridge, Robert C., Copland, John A. , Henderson, Ying C. , Lai, Stephen Y. , Clayman, Gary L. , Onoda, Naoyoshi , Tan, Aik Choon , García-Rendueles, María E.R. , Knauf, Jeffrey A. , Haugen, Bryan R. , Schweppe, Rebecca E. , Marlow, Laura A. , Knauf, Jeffrey A , Schweppe, Rebecca E , Tan, Aik Choon , Pozdeyev, Nikita V. , Fagin, James A.

Mayo Clinic

Clinical Cancer Research | February 8, 2019 | Volume: 25 | Issue: 10 | Pages: 3141-3151

10.1158/1078-0432.ccr-18-2953 | PMID 30737244 Get It

Abstract Purpose: Thyroid cancer cell lines are valuable models but have been neglected in pancancer genomic studies. Moreover, their misidentification has been a significant problem. We aim to provide a validated dataset for thyroid cancer researchers. Experimental Design: We performed next-generation sequencing (NGS) and analyzed the transcriptome of 60 authenticated thyroid cell lines and compared our findings with the known genomic defects in human thyroid cancers. Results: Unsupervised transcriptomic analysis showed that 94% of thyroid cell lines clustered distinctly from other lineages. Thyroid cancer cell line mutations recapitulate those found in primary tumors (e.g., BRAF, RAS, or gene fusions). Mutations in the TERT promoter (83%) and TP53 (71%) were highly prevalent. There were frequent alterations in PTEN, PIK3CA, and of members of the SWI/SNF chromatin remodeling complex, mismatch repair, cell-cycle checkpoint, and histone methyl- and acetyltransferase functional groups. Copy number alterations (CNA) were more prevalent in cell lines derived from advanced versus differentiated cancers, as reported in primary tumors, although the precise CNAs were only partially recapitulated. Transcriptomic analysis showed that all cell lines were profoundly dedifferentiated, regardless of their derivation, making them good models for advanced disease. However, they maintained the BRAFV600E versus RAS-dependent consequences on MAPK transcriptional output, which correlated with differential sensitivity to MEK inhibitors. Paired primary tumor-cell line samples showed high concordance of mutations. Complete loss of p53 function in TP53 heterozygous tumors was the most prominent event selected during in vitro immortalization. Conclusions: This cell line resource will help inform future preclinical studies exploring tumor-specific dependencies.
Timeline and location of recurrence following successful ablation in Barrett’s oesophagus: an international multicentre study
Sami, Sarmed S. , Ravindran, Adharsh, Snyder, Diana L. , Santiago, José , Ortiz‐Fernández‐Sordo, Jacobo , Tan, Wei Keith , Dierkhising, Ross , Johnson, Michele L., Lansing, Ramona, Ragunath, Krish , Pietro, Massimiliano di , Wolfsen, Herbert C. , Ramirez, Francisco C. , Fleischer, David E., Wang, Kenneth K, Leggett, Cadman L. , Katzka, David A. , Iyer, Prasad G. , Kahn, Allon , Snyder, Diana, Dierkhising, Ross A, Crook, Julia E. , Wolfsen, Herbert, Ramirez, Francisco, Fleischer, David, Katzka, D A , Iyer, P G , Leggett, Cadman L , Santiago, Jose, Heckman, Michael G.

Mayo Clinic

Gut | January 11, 2019 | Volume: 68 | Issue: 8 | Pages: 1379-1385

10.1136/gutjnl-2018-317513 | PMID 30635408 Get It

Objective Surveillance interval protocols after complete remission of intestinal metaplasia (CRIM) post radiofrequency ablation (RFA) in Barrett’s oesophagus (BE) are currently empiric and not based on substantial evidence. We aimed to assess the timeline, location and patterns of recurrence following CRIM to inform these guidelines. Design Data on patients undergoing RFA for BE were obtained from prospectively maintained databases of five (three USA and two UK) tertiary referral centres. RFA was performed until CRIM was confirmed on two consecutive endoscopies. Results 594 patients achieved CRIM as of 1 May 2017. 151 subjects developed recurrent BE over a median (IQR) follow-up of 2.8 (1.4–4.4) years. There was 19% cumulative recurrence risk of any BE within 2 years and an additional 49% risk over the next 8.6 years. There was no evidence of a clinically meaningful change in the recurrence hazard rate of any BE, dysplastic BE or high-grade dysplasia/cancer over the duration of follow-up, with an estimated 2% (95% CI −7% to 12%) change in recurrence rate of any BE in a doubling of follow-up time. 74% of BE recurrences developed at the gastro-oesophageal junction (GOJ) (24.1% were dysplastic) and 26% in the tubular oesophagus. The yield of random biopsies from the tubular oesophagus, in the absence of visible lesions, was 1% (BE) and 0.2% (dysplasia). Conclusions BE recurrence risk following CRIM remained constant over time, suggesting that lengthening of follow-up intervals, at least in the first 5 years after CRIM, may not be advisable. Sampling the GOJ is critical to detecting recurrence. The requirement for random biopsies of the neosquamous epithelium in the absence of visible lesions may need to be re-evaluated.
Neuroendocrine differentiation patterns in metastases from advanced prostate cancer.
Jiménez, Rafael E. , Nandy, Debashis, Qin, Rui , Carlson, Rachel E. , Tan, Winston , Kohli, Manish , Kohli, Manish

Mayo Clinic

Journal of Clinical Oncology | January 3, 2019 | Volume: 32 | Issue: 15_suppl | Pages: 5085-5085

10.1200/jco.2014.32.15_suppl.5085 Get It

Impact of beta-blocker medication use on prostate cancer survival: Results from a single-institution cancer registry.
Kohli, Manish , Nandy, Debashis, Tan, Winston , Tindall, Donald J., Pathak, Jyotishman , Breitenstein, Matthew K. , Kohli, Manish , Haley, Charlotte, Lee, Adam , Cerhan, James R.

Mayo Clinic

Journal of Clinical Oncology | January 3, 2019 | Volume: 32 | Issue: 15_suppl | Pages: e16064-e16064

10.1200/jco.2014.32.15_suppl.e16064 Get It